Pemetrexed for the maintenance treatment of non-small-cell lung cancer

NICE technology appraisals [TA190] Published date:

What has NICE said?

NICE recommends pemetrexed as a possible maintenance treatment for some people with non-small-cell lung cancer (see below).

Who can have pemetrexed?

You should be able to have pemetrexed if all the following apply:

  • you have locally advanced or metastatic non-small-cell lung cancer
  • squamous cell carcinoma is not the main type of cancer you have
  • you have not received pemetrexed and cisplatin together as a first treatment
  • your condition did not worsen immediately after you received platinum-based chemotherapy together with gemcitabine, paclitaxel or docetaxel.

Why has NICE said this?

NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE applies special considerations to treatments that can extend the lives of people who are nearing the end of their life. NICE recommended pemetrexed because the cost was justified by the benefits it provided when the special considerations were applied.

Get involved